SHANGHAI, CHINA--(MARKET WIRE)--Jun 21, 2007 -- Sinobiomed Inc. (“Sinobiomed”, or “the Company”) (OTC BB:SOBM.OB - News) is pleased to announce that its 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. (“Shanghai Wanxing”), has signed a sales contract with Bosch Pharmaceuticals (Pvt) Ltd. (“Bosch”) to export recombinant human Interferon alpha-2b to Pakistan.
